{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:22:31Z","timestamp":1785936151335,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00262-016-1898-2","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T08:36:27Z","timestamp":1473237387000},"page":"1395-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial"],"prefix":"10.1007","volume":"65","author":[{"given":"Paolo A.","family":"Ascierto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Vanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Maria","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Festino","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Palla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mozzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"issue":"5","key":"1898_CR1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1365-2133.2012.11125.x","volume":"167","author":"AM Forsea","year":"2012","unstructured":"Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC (2012) Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 167(5):1124\u20131130","journal-title":"Br J Dermatol"},{"issue":"4","key":"1898_CR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"issue":"4","key":"1898_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384","journal-title":"Lancet Oncol"},{"key":"1898_CR4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"key":"1898_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"1898_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1479-5876-11-54","volume":"11","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A et al (2013) The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 11:54","journal-title":"J Transl Med"},{"key":"1898_CR7","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Efficacy and safety in key patient subgroups of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-na\u00efve patients with advanced melanoma (CheckMate 067). European Society for Medical Oncology 2015 Congress. Presented September 28, 2015"},{"issue":"4","key":"1898_CR8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther 37(4):764\u2013782","journal-title":"Clin Ther"},{"issue":"8","key":"1898_CR9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"3","key":"1898_CR10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M et al (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114(3):256\u2013261","journal-title":"Br J Cancer"},{"key":"1898_CR11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0127","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. doi: 10.1158\/1078-0432.CCR-16-0127","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1898_CR12","first-page":"449","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ et al (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449\u2013458","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1898_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","volume":"50","author":"M Vecchio Del","year":"2014","unstructured":"Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J et al (2014) Efficacy and safety of ipilimumab 3\u00a0mg\/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 50(1):121\u2013127","journal-title":"Eur J Cancer"},{"issue":"1","key":"1898_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000441444","volume":"232","author":"V Prete Del","year":"2016","unstructured":"Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, Goldinger SM (2016) Noncutaneous melanomas: a single-center analysis. Dermatology 232(1):22\u201329","journal-title":"Dermatology"},{"key":"1898_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12967-015-0716-5","volume":"13","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P et al (2015) Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med 13:351","journal-title":"J Transl Med"},{"key":"1898_CR16","unstructured":"Larkin J, D\u2019Angelo SP, Sosman JA, Lebbe C, Brady B, Neyens B et al (2015) Efficacy and safety of nivolumab alone or in combination with ipilimumab in the treatment of advanced mucosal melanoma. Society for Melanoma Research 2015 Congress. Presented November 20, 2015"},{"key":"1898_CR17","unstructured":"Atkinson V, Ascierto PA, Long GV, Brady B, Dutriaux C, Maio M et al (2015) Two-year survival and safety update in patients with treatment-na\u00efve advanced melanoma (MEL) receiving nivolumab or dacarbazine in CheckMate 066. Presented at Society for Melanoma Research (SMR) 2015 International Congress, November 18\u201321, San Francisco, California, USA"},{"issue":"8","key":"1898_CR18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918","journal-title":"Lancet Oncol"},{"issue":"5","key":"1898_CR19","first-page":"449","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449\u2013458","journal-title":"Cancer Immunol Immunother"},{"key":"1898_CR20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-12-116","volume":"12","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M et al (2014) Clinical experience with ipilimumab 3\u00a0mg\/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116","journal-title":"J Transl Med"},{"key":"1898_CR21","first-page":"739","volume":"5","author":"M Mihajlovic","year":"2012","unstructured":"Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V (2012) Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 5:739\u2013753","journal-title":"Int J Clin Exp Pathol"},{"key":"1898_CR22","first-page":"38","volume":"3","author":"X Wang","year":"2014","unstructured":"Wang X, Si L, Guo J (2014) Treatment algorithm of metastatic mucosal melanoma. Chin Clin Oncol 3:38","journal-title":"Chin Clin Oncol"},{"key":"1898_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5694\/mja13.10448","volume":"201","author":"M Alexander","year":"2014","unstructured":"Alexander M, Mellor JD, McArthur G, Kee D (2014) Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 201:49\u201353","journal-title":"Med J Aust"},{"key":"1898_CR24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","volume":"18","author":"MA Postow","year":"2013","unstructured":"Postow MA, Luke JJ, Bluth MJ et al (2013) Ipilimumab for patients with advanced mucosal melanoma. Oncologist 18:726\u2013732","journal-title":"Oncologist"},{"key":"1898_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","volume":"2","author":"L Min","year":"2014","unstructured":"Min L, Hodi FS (2014) Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2:15\u201318","journal-title":"Cancer Immunol Res"},{"key":"1898_CR26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","volume":"76","author":"L Festino","year":"2016","unstructured":"Festino L, Botti G, Lorigan P et al (2016) Cancer treatment with anti-PD-1\/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs 76:925\u2013945","journal-title":"Drugs"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1898-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:08:45Z","timestamp":1498327725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1898-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1898-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]}}}